CoChat

An exploratory double‐blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

Open access
Süssmuth, Sigurd D., Haider, Salman, Landwehrmeyer, G. Bernhard, Farmer, Ruth, Frost, Chris, Tripepi, Giovanna, Andersen, Claus A., Di Bacco, Marco, Lamanna, Claudia, Diodato, Enrica, Massai, Luisa, Diamanti, Daniela, Mori, Elisa, Magnoni, Letizia, Dreyhaupt, Jens, Schiefele, Karin, Craufurd, David, Saft, Carsten, Rudzinska, Monika, Ryglewicz, Danuta, Orth, Michael, Brzozy, Sebastian, Baran, Anna, Pollio, Giuseppe, Andre, Ralph, Tabrizi, Sarah J., Darpo, Borje, Westerberg, Goran, the PADDINGTON Consortium · 2015 · British Journal of Clinical Pharmacology
Cited by 175

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aims: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease‐modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers. Methods: This was a randomized, double‐blind, placebo‐controlled, multicentre exploratory study. Fifty‐five male and female patients in early stage HD were randomized to receive 10 mg or 100 mg of selisistat or placebo once daily for 14 days. Blood sampling, clinical and safety assessments were conducted throughout the study. Candidate pharmacodynamic markers included circulating soluble huntingtin and innate immune markers. Results: Selisistat was found to be safe and well tolerated, and systemic exposure parameters showed that the average steady‐state plasma concentration achieved at the 10 mg dose level (125 n m) was comparable with the I C50 for SirT1 inhibition. No adverse effects on motor, cognitive or functional readouts were recorded. While circulating levels of soluble huntingtin were not affected by selisistat in this study, the biological samples collected have allowed development of assay technology for use in future studies. No effects on innate immune markers were seen. Conclusions: Selisistat was found to be safe and well tolerated in early stage HD patients at plasma concentrations within the anticipated therapeutic concentration range.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.12512

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 175

Metadata

Authors
Süssmuth, S. D., Haider, S., Landwehrmeyer, G. B., Farmer, R., Frost, C., Tripepi, G., Andersen, C. A., Di Bacco, M., Lamanna, C., Diodato, E., Massai, L., Diamanti, D., Mori, E., Magnoni, L., Dreyhaupt, J., Schiefele, K., Craufurd, D., Saft, C., Rudzinska, M., Ryglewicz, D., Orth, M., Brzozy, S., Baran, A., Pollio, G., Andre, R., Tabrizi, S. J., Darpo, B., Westerberg, G., & the PADDINGTON Consortium
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2015-02-20
Volume
79
Issue
3
Pages
465-476
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2131827606
Cited by
175
References
10
FWCI
3.62
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.